Sotorasib is a KRASG12C inhibitor that was recently approved in the US and by the European Commission for treating KRAS-mutated NSCLC that has progressed after at least one prior line of systemic therapy, but there is currently no therapeutic approach specifically targeting KRAS mutations in the first-line setting. This evidence concerns the gene KRAS and non-small cell lung carcinoma.